Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084386 | 0.92 | — | — | |
| SCHEMBL15095099 | 0.82 | MMP1 (0.36) | TSHRHPGDSMN1; SMN2 | |
| SCHEMBL16981760 | 0.80 | ALDH1A1 (0.37) | TSHRGAAHPGDSMN1; SMN2CHRM2 | |
| SCHEMBL17548904 | 0.80 | HPGD (0.30) | HPGDSMN1; SMN2 | |
| SCHEMBL16981758 | 0.78 | NAAA (0.36) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL14174584 | 0.78 | LMNA (0.34) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL26948072 | 0.78 | TSHR (0.36) | TSHR | |
| SCHEMBL271918 | 0.78 | — | — | |
| SCHEMBL15084385 | 0.77 | TSHR (0.30) | TSHR | |
| SCHEMBL9888822 | 0.77 | MGAM (0.38) | TSHRMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738039-B2 | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same | IBSA PHARMA SAS (FR) | 2023-08-29 | — | — | US | disclosed |
| US-20230190786-A1 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | IBSA PHARMA SAS (FR) | 2023-06-22 | — | — | US | disclosed |
| US-9669137-B2 | Modified polylactide polymers | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160175342-A1 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | GENBIOTECH (FR) | 2016-06-23 | — | — | US | disclosed |
| US-20150217028-A1 | MODIFIED PLA POLYMER AND METHOD OF MAKING AND USING | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150104380-A1 | Biodegredable Carrier For Carrying Radioisotope And Kit Containing The Same | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2015-04-16 | — | — | US | disclosed |
| US-8758828-B2 | Process for preparing cyclic esters comprising unsaturated functional groups and polyesters prepared from same | EVONIK CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8728528-B2 | Process for preparing microparticles having a low residual solvent volume | EVONIK CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130171261-A1 | Process for Preparing Cyclic Esters Comprising Unsaturated Functional groups And Polyesters Prepared From Same | EVONIK DEGUSSA CORPORATION (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130164381-A1 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation | SOUTHWEST RESEARCH INSTITUTE (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070503-A1 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation | SOUTHWEST RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110293690-A1 | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof | TYCO HEALTHCARE GROUP LP (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100316691-A2 | BIODEGRADABLE INTRAVAGINAL MEDICAL DEVICE FOR DELIVERY OF THERAPEUTICS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100166826-A1 | BIODEGRADABLE INTRAVAGINAL DEVICES FOR DELIVERY OF THERAPEUTICS | UNIVERSITY OF UATH RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090162407-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | EVONIK OPERATIONS GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20080249633-A1 | Biodegradable Materials and Methods of Use | WU TIM | 2008-10-09 | — | — | US | disclosed |
| US-7356368-B2 | Light-activated anti-infective coatings and devices made thereof | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7179867-B2 | Block polymer for a drug delivery system or embolic agents; adequate LCST (lower critical solution temperature) to reduce harm to tissues; polymer has units of a cholic acid, folic acid, or fatty acid-endcapped glycolide-lactide copolymer and ethylene glycol units optionally endcapped with methanol | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738039-B2 | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same | MUC1, CD44, MYOC | TSHR 3570/4885MGAM 97/4885GAA 17/4885 |
| US-20150104380-A1 | Biodegredable Carrier For Carrying Radioisotope And Kit Containing The Same | KIT, PGLS, TK1 | TSHR 1627/4885MGAM 877/4885GAA 44/4885 |
| US-20150217028-A1 | MODIFIED PLA POLYMER AND METHOD OF MAKING AND USING | PLAA, PARG, PHYKPL | TSHR 4794/4885MGAM 28/4885GAA 465/4885 |
| US-20100316691-A2 | BIODEGRADABLE INTRAVAGINAL MEDICAL DEVICE FOR DELIVERY OF THERAPEUTICS | IDUA, PGF, MMP1 | TSHR 4713/4885MGAM 276/4885GAA 277/4885 |
| US-20090162407-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | EXOSC9, PHOSPHO1, PLTP | TSHR 3391/4885MGAM 417/4885GAA 2217/4885 |
| US-20130164381-A1 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation | BMP2, SOST, BMPR1B | TSHR 3053/4885MGAM 4122/4885GAA 1840/4885 |
| US-20100166826-A1 | BIODEGRADABLE INTRAVAGINAL DEVICES FOR DELIVERY OF THERAPEUTICS | IDUA, MMP1, PGF | TSHR 4718/4885MGAM 383/4885GAA 191/4885 |
| US-20110293690-A1 | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof | PGF, TNF, CD68 | TSHR 3857/4885MGAM 459/4885GAA 167/4885 |
| US-20120070503-A1 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation | BMP2, SOST, BMPR1B | TSHR 3053/4885MGAM 4122/4885GAA 1840/4885 |
| US-20080249633-A1 | Biodegradable Materials and Methods of Use | BMP2, BMP6, BMP1 | TSHR 4712/4885MGAM 119/4885GAA 98/4885 |
| US-20230190786-A1 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | CD44, MUC1, GLA | TSHR 3310/4885MGAM 90/4885GAA 11/4885 |
| US-20160175342-A1 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | CD44, MUC1, GLA | TSHR 3310/4885MGAM 90/4885GAA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.